The drug Wegovy uses an active ingredient called Semaglutide which is part of a growing class of GLP-1 drugs that make people ...
Those taking the drugs for at least three years cut their risk of heart attack, stroke or cardiac death by 20 per cent ...
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount ...
Weight loss jabs like Ozempic can cut the risk of heart attacks or strokes by a fifth, a “game-changing” new study has found. The anti-obesity injections could reduce the risk in obese people ...
A weekly dose of Wegovy, alongside standard care for the prevention of heart attacks or stroke, lowered the risk by 20% ...
Patients taking semaglutide had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease after three ...
Research suggests that these drugs may reduce the risk of heart attack, stroke, and other cardiovascular issues even for ...
Marketed as Wegovy, Ozempic and Rybelsus, semaglutide injections may benefit obese patients even if they don't lose weight.
A groundbreaking study has revealed that an anti-obesity jab containing semaglutide, a drug used to treat obesity, significantly reduces the risk of heart attacks and strokes, regardless of the ...
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount of weight they lose while on the drug, researchers have found.
An anti-obesity drug could have additional health benefits including reducing the risk of heart attacks and strokes a new study has revealed. A five-year study was carried out by a team led by ...